drugset / Trial / NCT07255664
A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC
Phase 1/2
Recruiting
12 enrolled
CuraCell TX AB
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · collabKrebsforschung Rhein-Main e.V. · collabZellwerk GmbH · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a First-In-Human trial investigating a novel expansion protocol of an ATIMP (CC-38), composed of autologous TIL.
Timeline
- Start
- 2025-11-13
- Primary completion
- 2027-04
- Completion
- 2029-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CC-38 | Cell therapy | — | — |
| Background | 2-MERCAPTOETHANESULFONIC ACID | Small molecule | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Pembrolizumab | Monoclonal antibody | — | — |
| Background | aldesleukin | Protein / enzyme biologic | — | — |